Company intelligence / Profile preview
Eolas Therapeutics
Carlsbad, California, United Stateseolasthera.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
AZD4041, a highly selective orexin-1 receptor antagonist, completed Phase 1 studies and is advancing to Phase 2 trials for opioid and other substance use disorders, showing promising preclinical and early clinical results with no major drug-drug interactions anticipated[4].
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AstraZeneca (historic; licensing and R&D, collaboration concluded with Eolas regaining full rights in 2025[4])
Beyond the preview
Go deeper on Eolas Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eolas Therapeutics.